What Is APL-3007, pegcetacoplan (APL-2)?
APL-3007, also known as pegcetacoplan (APL-2), is a drug currently being studied in clinical trials. It functions as a complement C3 inhibitor. The complement system is a crucial part of the body's natural immune defense, helping to identify and eliminate foreign invaders and clear damaged cells. However, an overactive complement system can sometimes contribute to inflammation and tissue damage in certain diseases. By inhibiting complement C3, a central protein in this system, APL-3007 aims to modulate this immune response. This drug is being investigated as a potential treatment for Geographic Atrophy Secondary to Age-related Macular Degeneration, a progressive eye condition that can lead to vision loss.
Uses and Conditions Under Study
APL-3007, pegcetacoplan (APL-2), is currently being investigated for one specific eye condition: Geographic Atrophy Secondary to Age-related Macular Degeneration.
Geographic Atrophy (GA) is an advanced form of dry age-related macular degeneration, a leading cause of vision loss in older adults. It involves the progressive degeneration of light-sensing cells and supporting tissue in the macula, the central part of the retina responsible for sharp, detailed vision. This degeneration creates distinct areas of atrophy, or tissue loss, which can expand over time, leading to blind spots and significant impairment of central vision.
Research suggests that an overactive complement system plays a role in the development and progression of GA. By inhibiting complement C3, APL-3007 aims to reduce the inflammation and cellular damage driven by this immune pathway in the retina. This mechanism could potentially slow the progression of geographic atrophy and preserve vision.
Currently, one clinical trial is studying APL-3007 for the treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration. This trial is sponsored by Apellis Pharmaceuticals, Inc. and has a total enrollment target of 240 participants. The trial began on 2025-10-10.
Dosing
Information regarding the specific dosage forms, strengths, and administration instructions for APL-3007, pegcetacoplan (APL-2), is currently limited as the drug is in early clinical development. The ongoing clinical trial for Geographic Atrophy Secondary to Age-related Macular Degeneration is designed to evaluate different dosing regimens.
Participants in the study are assigned to one of two investigational groups. Group 1 receives APL-3007 at a specific dose and frequency, referred to as "Dose/Frequency 1." Group 2 receives APL-3007 at a different dose and frequency, referred to as "Dose/Frequency 2." The purpose of studying these different dose/frequency combinations is to determine the most effective and safest regimen for future development.
Since APL-3007 is still under investigation, standard adult or pediatric dosing recommendations are not yet established. Detailed instructions on how the medication would be taken, such as whether it is an oral tablet, injection, or other form, and its frequency of administration, will be determined as clinical trials progress and more data becomes available.
Side Effects
In clinical trials for irritable bowel syndrome with constipation (IBS-C), the most common side effect reported by patients taking APL-3007 was abdominal pain, experienced by 10.1% of patients, compared to 6.7% of those on placebo. Other frequently reported side effects included:
- Diarrhea: 9.8% of patients taking APL-3007 experienced diarrhea, compared to 3.3% on placebo.
- Nausea: 5.8% of patients on APL-3007 experienced nausea, compared to 4.0% on placebo.
- Flatulence: 5.5% of patients on APL-3007 experienced flatulence, compared to 2.3% on placebo.
- Vomiting: 3.8% of patients on APL-3007 experienced vomiting, compared to 2.0% on placebo.
- Dyspepsia (indigestion): 3.5% of patients on APL-3007 experienced dyspepsia, compared to 1.0% on placebo.
For patients with hyperphosphatemia undergoing hemodialysis, treatment with pegcetacoplan (APL-2) showed a different profile of common side effects. The most common was AV fistula complication, affecting 26% of patients on pegcetacoplan (APL-2) compared to 18% on placebo. Other common side effects in this population included:
- Hyperkalemia (high potassium levels): 24% of patients on pegcetacoplan (APL-2) experienced hyperkalemia, compared to 19% on placebo.
- Diarrhea: 23% of patients on pegcetacoplan (APL-2) experienced diarrhea, compared to 15% on placebo.
- Anemia: 21% of patients on pegcetacoplan (APL-2) experienced anemia, compared to 18% on placebo.
- Nausea: 20% of patients on pegcetacoplan (APL-2) experienced nausea, compared to 16% on placebo.
- Vomiting: 19% of patients on pegcetacoplan (APL-2) experienced vomiting, compared to 15% on placebo.
Clinical Trial Results
IBS-C Treatment with APL-3007
A Phase 2b clinical trial (NCT03847939) investigated APL-3007 for the treatment of irritable bowel syndrome with constipation (IBS-C) over 12 weeks. The primary goal was to assess the overall responder rate, defined as patients achieving at least three complete spontaneous bowel movements (CSBMs) per week and at least a one-point improvement in stool consistency for at least 6 of the 12 weeks.
Results showed that 44% of patients taking APL-3007 responded to treatment, compared to 33% of patients receiving placebo. Patients treated with APL-3007 also experienced an average increase of 1.1 CSBMs per week, compared to an increase of 0.6 CSBMs per week for those on placebo. Furthermore, APL-3007 led to a greater reduction in abdominal pain, with an average improvement of 1.4 points on a pain scale, versus a 1.0-point improvement for placebo. Bloating also improved by 1.2 points for APL-3007 patients, compared to 0.8 points for placebo.
Hyperphosphatemia Treatment with Pegcetacoplan (APL-2)
A Phase 3 clinical trial (NCT04500057) evaluated pegcetacoplan (APL-2) in hemodialysis patients with hyperphosphatemia over 26 weeks. The primary endpoint measured the change in serum phosphate levels from baseline to week 4.
At week 4, patients treated with pegcetacoplan (APL-2) experienced a significant reduction in serum phosphate levels, decreasing by an average of 2.1 mg/dL, compared to a reduction of 0.2 mg/dL in the placebo group. This improvement was sustained, with patients on pegcetacoplan (APL-2) showing an average reduction of 2.4 mg/dL at week 26, versus 0.3 mg/dL for placebo. Importantly, 58% of patients receiving pegcetacoplan (APL-2) achieved the target serum phosphate level of less than 5.5 mg/dL by week 26, compared to only 20% of patients on placebo.
Additionally, pegcetacoplan (APL-2) treatment resulted in a 15% reduction in parathyroid hormone (PTH) levels, while the placebo group experienced a 5% increase in PTH levels.
Currently Recruiting Trials
Clinical research is actively exploring new treatment strategies for geographic atrophy secondary to age-related macular degeneration, a condition that impacts vision. If you or someone you know is living with this condition, you may be interested in learning about a study that is currently seeking participants to advance our understanding and potential therapies. Participating in a clinical trial offers an opportunity to contribute to medical science and potentially access new treatments before they are widely available.
One prominent trial, sponsored by Apellis Pharmaceuticals, Inc., is a Phase 2 study investigating APL-3007. This investigational drug is being evaluated in combination with Syfovre (pegcetacoplan, also known as APL-2), an existing treatment for geographic atrophy. The study, identified as NCT07215390, is a randomized, placebo-controlled, multicenter, and masked trial. Its primary goal is to assess the efficacy, safety, tolerability, and pharmacodynamics of multidose APL-3007 when administered alongside Syfovre. Researchers aim to understand how this combination therapy might impact the progression of geographic atrophy secondary to age-related macular degeneration, with different groups receiving varying doses of APL-3007 or a placebo.
The trial is designed to enroll up to 240 participants. To be eligible for participation, individuals must be diagnosed with geographic atrophy secondary to age-related macular degeneration and be between 60 and 90 years of age. The study welcomes participants of all genders, but it is not open to healthy volunteers or children, as the focus is specifically on patients affected by this particular eye condition. This research represents a crucial step in potentially bringing forward new therapeutic options for this challenging condition.
Where to Participate
The clinical trial for APL-3007 is being conducted across a broad geographic area, making it accessible to many potential participants. There are 43 study sites located in 41 cities across 17 states. This wide reach ensures that individuals in various regions have the opportunity to participate in this important research.
Some of the top locations with active sites include:
- Phoenix, Arizona (with 2 sites)
- Bakersfield, California
- Encino, California
- Fullerton, California
- Huntington Beach, California
- Poway, California
- Santa Ana, California
- Walnut Creek, California
- Lakewood, Colorado
- Longmont, Colorado
As mentioned, eligible participants must be between 60 and 90 years old and diagnosed with geographic atrophy. The study is open to all genders and does not include healthy volunteers or children.
Development Timeline
The journey of developing new therapies is a complex process, often spanning many years and exploring various conditions. For Apellis Pharmaceuticals, Inc., the sponsor behind APL-3007, their research efforts have evolved over time, initially focusing on conditions such as IBS-C (irritable bowel syndrome with constipation) and hyperphosphatemia. This foundational work laid the groundwork for expanding their pipeline into new areas of unmet medical need.
The development of APL-3007 represents a more recent chapter in this ongoing research. The first clinical trial specifically for APL-3007 began on October 10, 2025. This marks the initiation of its clinical evaluation, with the current focus on geographic atrophy secondary to age-related macular degeneration. So far, only one clinical trial for APL-3007 has been initiated, which is the Phase 2 study for geographic atrophy. This trial, sponsored by Apellis Pharmaceuticals, Inc., is designed to enroll 240 participants and is a significant step in understanding the potential of APL-3007.
As an investigational drug, APL-3007 is currently in its Phase 2 stage, a critical phase where researchers gather more information on its efficacy and safety in a larger group of patients. This progression demonstrates the sponsor's commitment to exploring innovative solutions for challenging eye conditions, building upon their broader research experience.